Navigation Links
MacroGenics and Lilly Announce Pivotal Clinical Trial of Teplizumab Did Not Meet Primary Efficacy Endpoint
Date:10/20/2010

abetes as well as the impact of the DMC's recommendations on other potential indications."  

About Type 1 Diabetes

Type 1 diabetes is an autoimmune disease in which the body's immune system attacks and destroys the insulin-producing beta cells of the pancreas. Insulin is a hormone that is needed to convert sugar (glucose), starches and other food into energy needed for daily life. People with type 1 diabetes must take multiple injections of insulin daily or continually infuse insulin through a pump to manage their blood glucose levels.

Type 1 diabetes, previously known as juvenile diabetes, usually strikes in childhood, adolescence, or young adulthood, but lasts for a lifetime. Of the nearly 24 million Americans who have diabetes, as many as 3 million may have type 1.(i)

About Teplizumab

Teplizumab, also called MGA031 and hOKT3γ1 (Ala-Ala), is a humanized, anti-CD3 monoclonal antibody. Teplizumab binds to an epitope of the CD3-epsilon chain expressed on mature T lymphocytes and, by doing so, may modulate the pathological immunologic responses underlying multiple autoimmune diseases. Specifically, teplizumab may inhibit unwanted effector T cells and enhance beneficial regulatory T cell functions, thus promoting immune tolerance.  

About MacroGenics

MacroGenics is a private, venture-backed biotechnology company that focuses on the discovery, development and delivery to patients of novel biologics for autoimmune disorders, cancer and infectious diseases. Since its founding in 2000, the company has built a fully-integrated set of capabilities in monoclonal antibody product development. The company's product development efforts leverage three proprietary technology platforms: (1) cancer stem-like cells; (2) DART, which allows the company to incorporate multiple specificities within a single molecule; and (3) Fc optimization, which enhances antibody-dependent effector function
'/>"/>

SOURCE Eli Lilly and Company
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. MacroGenics Begins Global Phase 2/3 Protege Study in Recent-onset Type 1 Diabetes Mellitus
2. MacroGenics and Lilly Achieve Targeted Patient Enrollment in PROTEGE, a Global Phase 2/3 Clinical Trial of Teplizumab in Type 1 Diabetes
3. FDA Approves Lillys Osteoporosis Drug EVISTA(R) (raloxifene HCl) to Reduce The Risk of Invasive Breast Cancer in Two Populations of Postmenopausal Women
4. Lilly Files for European Approval of ALIMTA(R) (pemetrexed for injection) for First-Line Treatment of Non-Small Cell Lung Cancer
5. Lilly and Glenmark Pharmaceuticals Announce License Agreement
6. Lilly Receives NCQA Design Certification for Depression Care Management Program
7. JDRF and Lilly Partner to Fund Research to Identify Beta Cell Biomarkers
8. FDA Grants Priority Review for Daiichi Sankyo, Lilly Drug, prasugrel
9. Statement from Eli Lilly and Company: Response to Connecticut Attorney General News Release
10. Lilly and Transition Therapeutics Announce Licensing and Collaboration Agreement
11. Lilly Launches Its First Phase III Trial for Treatment of Alzheimers Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... 2014 The medical magnetic resonance imaging ... 4%, with world market revenues for 2013 at ... other types of medical imaging have led to ... medical conditions in children and adults, each imaging ... Medical Imaging Markets , analyzes the current ...
(Date:11/26/2014)... , Nov. 25, 2014  goBalto, Inc., the ... been recognized as a winner of Red Herring,s ... Global Top 100 North America award in 2013, marking ... technology landscape. Red Herring,s Top 100 Global ... promising new companies and entrepreneurs. Red Herring editors were ...
(Date:11/26/2014)... 25, 2014   Heska Corporation (NASDAQ: ... a provider of advanced veterinary diagnostic and other specialty ... Executive Chair, will attend The Benchmark Company, LLC,s Micro Cap ... will be held at The Palmer House Hilton, 17 E. ... a.m. to 2:30 p.m. Please email hska@haydenir.com or ...
Breaking Medicine Technology:Kalorama: Steady Growth in the Medical MRI Market 2Kalorama: Steady Growth in the Medical MRI Market 3goBalto Selected as a 2014 Red Herring Top 100 Global Company 2goBalto Selected as a 2014 Red Herring Top 100 Global Company 3Heska to Attend Benchmark Micro Cap Discovery Conference 2
... 5 Rochester Medical Corporation (Nasdaq: ROCM ) today ... September 30, 2009. , The Company reported sales of $9,009,000 ... quarter of last year. The Company reported a quarterly ... to net income of $342,000 or $.03 per diluted share ...
... , SADDLE RIVER, N.J., Nov. 5 ... of sales and marketing support to U.S. pharmaceutical companies, today ... September 30, 2009. , Commenting on today,s announcement, Nancy ... 2009 revenues of $21.0 million were lower than last year ...
Cached Medicine Technology:Rochester Medical Reports Fourth Quarter and Annual Results and Announces Final Medicare Approval for Reimbursement for the FEMSOFT(R) Insert 2Rochester Medical Reports Fourth Quarter and Annual Results and Announces Final Medicare Approval for Reimbursement for the FEMSOFT(R) Insert 3Rochester Medical Reports Fourth Quarter and Annual Results and Announces Final Medicare Approval for Reimbursement for the FEMSOFT(R) Insert 4Rochester Medical Reports Fourth Quarter and Annual Results and Announces Final Medicare Approval for Reimbursement for the FEMSOFT(R) Insert 5Rochester Medical Reports Fourth Quarter and Annual Results and Announces Final Medicare Approval for Reimbursement for the FEMSOFT(R) Insert 6Rochester Medical Reports Fourth Quarter and Annual Results and Announces Final Medicare Approval for Reimbursement for the FEMSOFT(R) Insert 7Rochester Medical Reports Fourth Quarter and Annual Results and Announces Final Medicare Approval for Reimbursement for the FEMSOFT(R) Insert 8Rochester Medical Reports Fourth Quarter and Annual Results and Announces Final Medicare Approval for Reimbursement for the FEMSOFT(R) Insert 9Rochester Medical Reports Fourth Quarter and Annual Results and Announces Final Medicare Approval for Reimbursement for the FEMSOFT(R) Insert 10Rochester Medical Reports Fourth Quarter and Annual Results and Announces Final Medicare Approval for Reimbursement for the FEMSOFT(R) Insert 11Rochester Medical Reports Fourth Quarter and Annual Results and Announces Final Medicare Approval for Reimbursement for the FEMSOFT(R) Insert 12PDI Reports 2009 Third Quarter Financial Results 2PDI Reports 2009 Third Quarter Financial Results 3PDI Reports 2009 Third Quarter Financial Results 4PDI Reports 2009 Third Quarter Financial Results 5PDI Reports 2009 Third Quarter Financial Results 6PDI Reports 2009 Third Quarter Financial Results 7PDI Reports 2009 Third Quarter Financial Results 8PDI Reports 2009 Third Quarter Financial Results 9PDI Reports 2009 Third Quarter Financial Results 10PDI Reports 2009 Third Quarter Financial Results 11
(Date:11/27/2014)... HealthDay Reporter , WEDNESDAY, Nov. 26, 2014 (HealthDay ... second language, new research suggests. But anyone who tries to ... boost, the small study finds. The brain "becomes ... Li, co-director of the Center for Brain, Behavior and Cognition ... said, that "the brain networks of the more successful learners ...
(Date:11/27/2014)... New York, NY (PRWEB) November 27, 2014 ... devoted to offering stylish, comfortable and high functioning compression socks, ... line. The newly-released socks use an innovative Gradient Pressure (TM) ... freshly oxygenated blood. , VIM & VIGR’s commitment to adding ... thought of as just functional recently caught the eye of ...
(Date:11/27/2014)... VogueQueen.com is making every effort to offer ... world. As the premier online supplier of elegant special ... release a huge selection of sexy prom dresses today. ... also providing many beautiful styles in its product line. ... discounted prices. , “VogueQueen.com hopes to provide a truly ...
(Date:11/27/2014)... Texas (PRWEB) November 27, 2014 ... report on Global Insulin industry. For an overview ... definition, classification, application, industry chain structure, industry overview, ... on global Insulin industry covers information on ... process, product cost structure and much more. ...
(Date:11/27/2014)... "The uglier, the better," says Dr. Kirk ... full of laughter as we enjoy the ugly sweater contest." ... sweater from scratch. " It was a sight to see. ... weren't ridiculous enough, the Christmas balls were faces of the ... interested in participating this year, it's simple to get in ...
Breaking Medicine News(10 mins):Health News:Some People May Be Pre-Wired to Be Bilingual 2Health News:Some People May Be Pre-Wired to Be Bilingual 3Health News:VIM & VIGR Announces Launch of Men’s Line of Compression Socks 2Health News:A New Collection of Sexy Prom Dresses Has Been Released by the Reliable Online Supplier VogueQueen.com 2Health News:Insulin Industry Analysis (Supply, Consumption) for China, America, Korea, France & Japan Research Now at ReportsnReports 2Health News:Insulin Industry Analysis (Supply, Consumption) for China, America, Korea, France & Japan Research Now at ReportsnReports 3Health News:Verde Pointe Dental Associates Hosts 2014 Ugly Holiday Sweater Contest 2Health News:Verde Pointe Dental Associates Hosts 2014 Ugly Holiday Sweater Contest 3
... treatment for type 1 diabetes in future, , MONDAY, Aug. ... with type 1 diabetes, researchers were able to produce cells ... though not as efficiently as normal insulin-producing cells do. , ... now have a preliminary lab model of human type 1 ...
... BOSTON -- Appropriately selected prostate cancer patients, including ... defer treatment for many years with no adverse consequences, according ... Oncology (JCO). Led by researchers at Beth Israel Deaconess ... the advent of PSA [prostate antigen] screening nearly 20 years ...
... Blue ... , ... The emergence of the new H1N1 (swine) flu puts increased emphasis on preparing early for the ... urged to get their flu shot as soon as possible. Since both the seasonal flu and ...
... , Safety tips also offered as fires threaten ... American Red Cross is on the scene offering evacuees a safe place ... scorch thousands of acres. Overnight, nearly 200 people took refuge from the ... (Logo: http://www.newscom.com/cgi-bin/prnh/20090108/RedCrossLOGO ) , , "If ...
... , SANTA CLARA, Calif., Aug. ... September, medical students begin searching for residency training programs. ... students have fewer dollars available to visit multiple residency programs. ... technology, is responding to this need by hosting both an ...
... COCONUT CREEK, Fla., Aug. 31 e-Telmed, Inc., ... solution provider and Synergistic Healthcare, a national leader in distributing ... announced today that they have signed an exclusive agreement. This ... the delivery of healthcare in the U.S., it creates a ...
Cached Medicine News:Health News:Researchers Make Insulin-Producing Cells From Adult Skin Cells 2Health News:Researchers Make Insulin-Producing Cells From Adult Skin Cells 3Health News:'Watchful waiting' is a viable option for prostate cancer patients with low-risk tumors 2Health News:'Watchful waiting' is a viable option for prostate cancer patients with low-risk tumors 3Health News:Flu Season Preparation Comes Early 2Health News:Flu Season Preparation Comes Early 3Health News:Flu Season Preparation Comes Early 4Health News:Red Cross Shelters Wildfire Evacuees 2Health News:Red Cross Shelters Wildfire Evacuees 3Health News:Kaiser Permanente Residency Program Open House 2Health News:e-Telmed, Inc., the Leading Telehealth Solution Provider, Signs Exclusive Agreement with Synergistic Healthcare 2
Coronary angiographic catheter...
Leksell Neuro Generator is a complete system for stereotactic lesioning, pain treatment, stimulation and bipolar coagulation. It features a radio frequency (RF) energy source with sophisticated, inte...
... a complete offering of cardiology catheters. Available ... catheters are designed with excellent torque, new ... better push-ability, and large inner lumens for ... 6 and 7 French sizes with pressure ...
The Compass Commander series is engineered to provide the discriminating neurosurgeon with the same capabilities offered within the commander plus+, all in a smaller, lower-cost package....
Medicine Products: